MAIA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer...

Stats
Today's Volume	437 552
Average Volume	324 442
Market Cap	40.06M
EPS	$0 ( 2024-03-22 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.990
ATR14	$0.0140 (0.48%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	Louie Ngar Yee	Buy	19 665	Common Stock
2024-04-25	Louie Ngar Yee	Buy	19 665	Warrants
2024-04-25	Smith Stan	Buy	147 492	Common Stock
2024-04-25	Smith Stan	Buy	147 492	Warrants
2024-03-31	Smith Stan	Buy	11 491	Stock Options

INSIDER POWER
98.97
Last 99 transactions
Buy: 2 992 422 \| Sell: 15 000

Volume Correlation

Long: 0.17 (neutral)

Short: 0.15 (neutral)

Signal:(43.803) Neutral

MAIA Biotechnology, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MAIA Biotechnology, Inc. Correlation - Currency/Commodity

0.16
( neutral )

0.04
( neutral )

0.00
( neutral )

0.05
( neutral )

0.06
( neutral )

0.57
( weak )

MAIA Biotechnology, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.700

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.700

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.223

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.649

Financial Reports:

No articles found.

MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.